Liver Transplant; Complications Clinical Trial
— LIVER-PAMOfficial title:
High Versus Low Blood-Pressure Target in the Post Operative Care of Liver Transplantation
Verified date | January 2024 |
Source | University of Sao Paulo General Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
LIVER PAM A randomized, controled, open and unicentric trial comparing high (MAP 85-90 mmHg) and low (65-70 mmHg) target of mean arterial pressure in the first 24 hours after liver transplantation.
Status | Completed |
Enrollment | 174 |
Est. completion date | January 5, 2024 |
Est. primary completion date | January 5, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Older than 18 y - Admitted in the ICU for a post operative care after liver transplant Exclusion Criteria: - Consent refusal - Liver transplant due to acute liver failure - Renal transplant ( Previous or concomitant) - Refusal from the healthcare provider responsible for the patient - Renal substitution therapy in the prior 15 days - Pregnancy - Re-Transplant (Liver transplant in the previous 6 month) - Hepatorenal syndrome current treatment (Use of terlipressin + Albumin) - Refractory and persistent shock during or after transplant |
Country | Name | City | State |
---|---|---|---|
Brazil | Hospital Das Clínicas Da Faculdade de Medicina Da Universidade de São Paulo | São Paulo | SAO Paulo |
Lead Sponsor | Collaborator |
---|---|
University of Sao Paulo General Hospital |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | incidence of Acute Kidney Disfunction | Incidence of acute kidney Disfunction according to kdigo criteria. | 7 days | |
Secondary | Mortality | percentage of mortality in 28 days | 28 days | |
Secondary | re-transplant | percentage of re-transplant in 28 days | 28 days | |
Secondary | Lenght of Hospitay Stay | LOS in 28 days | 28 days | |
Secondary | Lenght of ICU Stay | ICU LOS in 28 days | 28 days | |
Secondary | Days alive and out of hospital in 28 days | Number of days alive and out of hospital in 28 days | 28 days | |
Secondary | Substitutive Renal Therapy | percentage of TSR in 7 days | 7 days | |
Secondary | Days Alive and free of renal disfunction | Days Alive and free of renal disfunction in 28 days | 28 days | |
Secondary | Acute kidney insufficiency according to Urinary NGAL on d0 and D2 | Percentage of renal disfunction according to NGAL criteria on D0 and D2 | 0d and 2d | |
Secondary | MAKE28 | Major Kidney Events ( Death, persistent acute kidney disfunction or need of RRT in 28 days) | 28 days | |
Secondary | Liver graft primary disfunction ( Initial Poor Function) | percentage of Initial Poor Function in 7 days | 7 days | |
Secondary | Liver graft primary disfunction (primary nonfunction) | percentage of primary nonfunction in 10 days | 10 days | |
Secondary | Surgical site infection | percentage of SSI in 28 days | 28 days | |
Secondary | Need of Transfusion | percentage of Transfusion requirement in 7 days | 7 days | |
Secondary | Postoperative Major bleeding in 7 days | Bleeding that requires 2 units of blood transfusion in a single day or the need of a reoperation due to bleeding in the first 24 hours after surgery. | 7 days | |
Secondary | Incidence of Arrythmia requiring clinical treatment | percentage of Arrhythmia requiring treatment in 7 days | 7 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05818644 -
Hepatic Artery Stenosis and Thrombosis After Liver Transplantation in Children
|
||
Not yet recruiting |
NCT06041490 -
Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation
|
Phase 2 | |
Recruiting |
NCT04443322 -
Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )
|
N/A | |
Recruiting |
NCT05081141 -
HHV8 and Solid Organ Transplantation
|
||
Completed |
NCT03165916 -
Study to Compare the Incidence of Biliary Complications After Liver Transplantation
|
N/A | |
Withdrawn |
NCT04216303 -
Optimal A1c Control in Post Liver or Combined Liver and Kidney Transplant Recipients Who Have Diabetes Mellitus
|
||
Recruiting |
NCT04506398 -
Heterogeneity and Evolution of hepatoceLlular Carcinoma in Post-transplant HCC Recurrence
|
||
Not yet recruiting |
NCT05853484 -
Home-based Bimodal Lifestyle Intervention in Patients With Liver Cirrhosis Awaiting Orthotopic Liver Transplantation
|
N/A | |
Not yet recruiting |
NCT05036031 -
Transplantation for EASL-CLIF and APASL ACLF Patients: a Retrospective Cohort Study
|
||
Recruiting |
NCT05065125 -
Clinical Usefulness of Digital Single-operator Cholangioscopy(SpyGlass™) for Post-liver Transplant Anastomotic Stricture
|
||
Recruiting |
NCT06060392 -
Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus
|
N/A | |
Enrolling by invitation |
NCT05195944 -
Semaglutide vs Sitagliptin
|
Phase 4 | |
Completed |
NCT05255510 -
Risk of Acute Kidney Injury in Living Liver Donor Surgery
|
||
Not yet recruiting |
NCT06048445 -
Placement of Biliary Drainage Stent to Prevent Biliary Intestinal Anastomosis After Liver Transplantation in Children
|
||
Completed |
NCT05116748 -
COVID19 Vaccine in SOT Adult Recipients
|
||
Completed |
NCT04182256 -
Magnetic Spiderman for Preparation of Liver Donation
|
N/A | |
Recruiting |
NCT04327427 -
Outcome Analysis of Aspirin in Liver Transplantation
|
||
Recruiting |
NCT04477967 -
Design and Implementation of the Pediatric Liver Transplantation Biobank
|
||
Recruiting |
NCT05109156 -
Preoperative Sepsis Timeline, Profile and Its Association With Recipient Outcome Following Live Donor Liver Transplant
|
||
Recruiting |
NCT06124209 -
Use of Fibrin Sealant Patch for Vein Anastomosis During Deceased Donor Liver Transplantation- Randomized Clinical Trial
|
Phase 4 |